Abvc biopharma receives $3.175 million investment from the lind partners to continue clinical trials

Fremont, ca, feb. 23, 2023 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the "investment") with lind global fund ii, lp, an investment fund managed by the lind partners (together “investor” or “lind”), a new york-based institutional fund manager.
ABVC Ratings Summary
ABVC Quant Ranking